DEXCOM INCDXCM
DEXCOM INC Financial Overview 2021–2025
Updated Aug 15, 2026Dexcom delivered a 45% jump in net income to $836.3 million in FY2025, proving it can translate its rapidly expanding diabetic customer base into highly scaled profitability. The company's focus on disposable continuous glucose monitoring (CGM) sensors has cemented its status as a cash-generating engine capable of sustaining consistent top-line growth.
This operational leverage is evident across a multi-year timeline. Dexcom nearly doubled its top line, as revenue grew from $2.45 billion in FY2021 to $4.66 billion in FY2025. The core driver was global adoption of the G7 system and the new Stelo biosensor, which brought in an estimated 600,000 to 700,000 net new customers during FY2025. As sales volume climbed, operating income surged 52% year-over-year to $911.8 million in FY2025, demonstrating that overhead is being tightly managed even during aggressive product rollouts.
The company ended FY2025 holding a liquidity cushion of $2.00 billion in cash and marketable securities. At the close of FY2025, the market valued Dexcom at a $25.5 billion market capitalization, with the stock priced at $66.37 and trading at a multiple of 31.8x earnings.
Recent Developments (Q1 and Q2 2026)
Dexcom sustained top-line growth and margin expansion through the first half of 2026. Revenue climbed 13% year-over-year to $1.31 billion in Q2 2026, building on a 15% increase in Q1 2026. Manufacturing efficiencies pushed gross margins to 63.4% in the second quarter, driving a 50% increase in operating income to $318.3 million.
In May 2026, management set long-term targets of 10%+ annual organic revenue growth and 67-69% gross margins by 2030. The board authorized a $1.00 billion share repurchase program, executing $600.0 million in buybacks by mid-year. Bulls point to these aggressive buybacks and operating cash flow—which spiked 186% year-over-year to $525.6 million in the first quarter—as proof of strong core profitability. Bears argue the equity trades at a premium multiple of 35.7x earnings as of July 30, 2026, leaving the valuation highly vulnerable to any escalation in ongoing product and securities litigation.
What to watch: progress toward 2030 profit margin targets; developments in active product and securities litigation
Rev
$4.66B
FY2025
NI
$836.3M
FY2025
EPS
$2.14
FY2025
OCF
$1.44B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
All DXCM Financial Metrics(58)
Income Statement
Balance Sheet
- Cash & ST Investments
- Total Assets
- Current Assets
- Cash
- Short-Term Investments
- Receivables
- Inventory
- Prepaid & Other
- PP&E
- Goodwill
- Intangibles
- Other Non-current
- Total Liabilities
- Current Liabilities
- Deferred Revenue
- Long-Term Debt
- Other Non-current Liab.
- Equity
- Retained Earnings
- Accumulated OCI
- APIC
- Treasury Stock
- Total L&E
- Shares Outstanding
Cash Flow
Recent SEC Filings
DEXCOM INC 8-K Report, Financial Results (Jul 30, 2026)
DexCom, Inc. (DXCM) has filed an 8-K report on July 30, 2026, to disclose its financial results for the second quarter ended June 30, 2026. The primary purpose of this filing is to furnish a press release announcing these results, which provides investors with key performance indicators and financial condition updates. While this information is furnished and not deemed 'filed' for liability purposes under Section 18 of the Exchange Act, it represents the company's official communication regarding its recent performance. Investors should refer to the press release (Exhibit 99.1) for specific details on revenue, profitability, and any forward-looking statements or guidance provided by DexCom for the upcoming periods. The filing indicates that further details beyond the summary provided in the 8-K's Item 2.02 will be found within this attached press release, which is crucial for a comprehensive understanding of the company's current financial standing and future outlook.
DEXCOM INC 8-K Report, Shareholder Vote Results (May 28, 2026)
DexCom, Inc. (DXCM) held its 2026 Annual Meeting of Stockholders on May 27, 2026, where key corporate governance and operational matters were presented to shareholders for a vote. The meeting saw strong participation, with a quorum established by the presence of 336,525,352 shares, representing over 87% of the outstanding common stock as of the April 1, 2026 record date. The primary outcomes of the meeting include the re-election of all twelve nominated directors to the board, each for a term extending to the 2027 annual meeting. Furthermore, stockholders overwhelmingly ratified the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The compensation of the company's named executive officers was also approved on an advisory, non-binding basis.
DEXCOM INC 8-K Report, Regulation FD Disclosure (May 15, 2026)
DEXCOM INC. (DXCM) filed an 8-K on May 15, 2026, detailing key strategic and financial announcements made during their 2026 Investor Day. The company presented ambitious long-range financial targets through 2030, emphasizing sustained organic revenue growth and significant improvements in profitability margins. These targets signal strong confidence in Dexcom's market position and future performance, which will be closely watched by investors. In addition to outlining its growth trajectory, Dexcom's Board of Directors approved a substantial $1.0 billion share repurchase program, signaling a commitment to returning capital to shareholders and potentially enhancing shareholder value. This strategic move, coupled with the long-term financial outlook, provides investors with a comprehensive view of Dexcom's forward-looking strategy, focusing on both growth initiatives and capital allocation.
DEXCOM INC 8-K Report, Financial Results (Apr 30, 2026)
DexCom, Inc. (DXCM) has filed an 8-K report on April 30, 2026, to announce its financial results for the first quarter ended March 31, 2026. While the filing itself is brief, it references a press release (Exhibit 99.1) containing the detailed financial and operational performance for the period. Investors should refer to this press release for crucial information regarding revenue, profitability, and any forward-looking guidance provided by the company. This filing serves as a notification mechanism for material updates. The company's performance in Q1 2026, as detailed in the press release, will be a key indicator for assessing its current trajectory and future prospects. Investors are advised to examine the press release for specific metrics and commentary that could influence their investment decisions, paying close attention to any management commentary on market trends, product adoption, and competitive landscape.
DEXCOM INC 8-K Report, Executive Changes (Mar 2, 2026)
This 8-K filing from DexCom, Inc. (DXCM) on March 2, 2026, primarily reports on the return of Kevin R. Sayer to his role as Executive Chairman of the Board, effective March 2, 2026, after a temporary leave of absence. Mr. Sayer's transition from CEO to Executive Chairman was previously announced, and his return signifies a continuation of his leadership and strategic guidance for the company. This filing also details the new compensation arrangement for his role as Executive Chairman.
View all 8-K filings →